Does HGH fragment 176-191 actually burn fat?
176-191 has clear lipolytic action in animal models, but the human trial data — through its analog AOD-9604 — did not beat placebo for clinically meaningful fat loss.
Updated May 8, 2026 · 4 min read
The short answer is: a little, probably, but not enough to matter on its own. HGH fragment 176-191 has a clear lipolytic mechanism and reliable effects in animal models. The human evidence — collected mostly through its more-developed analog AOD-9604 — has been disappointing. Multiple randomized trials in humans failed to show that 176-191-class peptides beat placebo on weight or fat-mass endpoints meaningful enough to justify drug development.
What 176-191 is supposed to do
The fragment is the C-terminal 16 amino acids of human growth hormone (residues 176–191). The original premise was elegant: this region of the GH molecule was theorized to carry the lipolytic (fat-burning) activity of full GH, without the IGF-1, glucose-disrupting, or proliferative effects that limit GH for body-composition use. That would make it a "clean" fat-loss tool — all the burn, none of the side effects.
In animals, that premise mostly held up. Rodent studies showed:
- Increased lipolysis in adipose tissue
- No change in fasting glucose
- No change in IGF-1 or proliferative markers
- Modest body-fat reduction over weeks
That's the case for the peptide on paper.
What the human trials actually showed
The most rigorous human data comes from AOD-9604, a modified version of 176-191 developed by Metabolic Pharmaceuticals (Australia) for obesity. Multiple randomized, placebo-controlled trials were run from the early 2000s into the early 2010s.
| Trial | Result |
|---|---|
| Phase 2 obesity trial, 12 weeks | No significant fat-loss difference vs. placebo at the trial endpoint |
| Multiple dose-finding studies | Lipolytic activity confirmed but small in magnitude |
| Safety — repeated administration | Generally well-tolerated, no major adverse events |
The drug development program for obesity was eventually discontinued. AOD-9604 was repositioned and now circulates as a research-chemical and a "wellness" peptide — sold widely, but not because the obesity trials succeeded.
That history matters. When 176-191 is sold as "fat-loss without GH side effects," what's typically not mentioned is that the largest clinical program for the same molecular family failed its weight-loss endpoint.
What users actually experience
In real-world strength and recovery community reports, the typical pattern is:
- Modest scale movement (1–3 lb fat loss over 8–12 weeks) on an aggressive cut, on top of caloric deficit and training
- No notable IGF-1 spike, no glucose disruption — confirming the mechanistic claim
- No appetite suppression (this is not a GLP-1 — it doesn't touch hunger pathways)
- Minimal injection-site issues; well-tolerated
The honest framing: 176-191 is doing something, but the something is small enough that you cannot reliably distinguish it from diet, training adherence, and water-weight changes without controlled measurement.
Where it does and doesn't fit
Does fit:
- An accessory in a tightly-controlled cut where the user is already dialed in on diet and training, has measured baseline body comp, and can run an 8–12 week protocol
- Stacks with other peptides for users who want layered support without the GH side-effect profile (water retention, glucose, joints)
Doesn't fit:
- A standalone fat-loss tool — diet drives 90%+ of the result
- A replacement for GLP-1 agonists if appetite control is the actual problem
- An "easy mode" cut — there is no easy mode
How it stacks against alternatives
| Tool | Mechanism | Realistic effect |
|---|---|---|
| HGH frag 176-191 / AOD-9604 | Direct lipolysis, no IGF-1 spike | Small; under 5 lb extra fat loss in 12 weeks vs. diet alone |
| GH secretagogues (ipamorelin + CJC-1295) | Endogenous GH pulse, full GH signaling | Moderate; better recomposition than 176-191 |
| GLP-1 agonists (semaglutide, tirzepatide) | Appetite suppression + glucose modulation | Large; the dominant pharmacological fat-loss option |
| Caffeine + diet adherence | CNS, NEAT increase, deficit | The actual driver |
If your reason for wanting 176-191 is "cleaner than full GH," the case is reasonable. If your reason is "I want fast fat loss," the trial record says you'll be disappointed.
Dosing and safety
Typical dosing in the research-chemical community is 250–500 mcg subQ once or twice daily, often pre-cardio or upon waking. There is no FDA-approved human formulation; supply quality varies dramatically — see how to spot fake peptides and what does a COA show.
Side effects are uncommon at typical doses. Mild flushing, occasional injection-site irritation, and rare reports of fatigue. No reliable signal for IGF-1 elevation, glucose disruption, or joint issues — which matches the mechanistic claim.